Qorvo Omnia™ SARS-CoV-2 Antigen Test
In April 2021, Qorvo were granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Qorvo Omnia™ SARS-CoV-2 Antigen Test. The EUA approval is a major milestone in the collaboration between Qorvo and SCHOTT MINIFAB over the past two years.
Assay Maturity – Is Your Assay Ready for Microfluidic Commercialisation?
Are you developing a diagnostic microfluidic product? Validating assay maturity is critical for commercial success.
Case Study: TearLab and SCHOTT MINIFAB – A Microfluidic Manufacturing Success Story
The TearLab success story began in 2007 when SCHOTT MINIFAB was approached to help turn the early stage eye health concept into a commercial product.
The relationship between TearLab and SCHOTT MINIFAB came at a pivotal moment. Prior to this partnership TearLab had invested considerable time and money with another developer / manufacturer only to be told that the concept was unworkable. Many other microfluidics experts had also voiced the opinion that the product was a technical impossibility.
